First-pass extracted concept

clozapine-N-oxide

Candidate: concept label3 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

CNO

Extracted Explainers

What the tool is doing

Clozapine-N-oxide is used here as the second chemogenetic actuator for cross-validating the suppression results.

Source 2DOI PubMed

Resources required

Its use requires a compatible chemogenetic setup, though the abstract does not specify the construct or dosing details.

Source 2DOI PubMed

What problem it solves

It provides an alternative actuator condition for testing whether the observed effects are consistent across chemogenetic activation conditions.

Source 2DOI PubMed

What it does not solve

The abstract does not clarify pharmacokinetic interpretation or off-target effects.

Source 2DOI PubMed

Alternatives

The abstract explicitly contrasts CNO with clozapine.

Source 2DOI PubMed

Evidence Snippets

AAV5, oral administration of deschloroclozapine, and clozapine-N-oxide were also effective but with slightly less potency.

Evidence 1Source 1DOI PubMedprovenance

Our results were cross-validated using two different chemogenetic actuators, clozapine (CLZ) and clozapine-N-oxide (CNO).

Evidence 2Source 2DOI PubMedprovenance

We show fast glial response upon clozapine-N-oxide (CNO) administration in cortical and subcortical regions.

Evidence 3Source 3DOI PubMedprovenance

Supporting Sources

Source 1primary paper2024MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 2primary paper2024MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 3primary paper2024MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Linked Claims

Claim 1comparative efficacysupports2024Source 1DOI PubMed

AAV5, oral deschloroclozapine, and clozapine-N-oxide were effective but slightly less potent than the strongest reported condition.

Quoted textsource-backed

AAV5, oral administration of deschloroclozapine, and clozapine-N-oxide were also effective but with slightly less potency.

Claim 2cross validationsupports2024Source 2DOI PubMed

The reported results were cross-validated using clozapine and clozapine-N-oxide as two chemogenetic actuators.

Quoted textsource-backed

Our results were cross-validated using two different chemogenetic actuators, clozapine (CLZ) and clozapine-N-oxide (CNO).

Claim 3temporal responsesupports2024Source 3DOI PubMed

Glial responses occur rapidly after clozapine-N-oxide administration in cortical and subcortical regions.

Quoted textsource-backed

We show fast glial response upon clozapine-N-oxide (CNO) administration in cortical and subcortical regions.